Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TL011
- Development stage
- Phase 1
- Lead developer
- Teva Pharmaceutical Industries
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TL011 is an anti-CD20 monoclonal antibody biosimilar candidate developed by Teva Pharmaceutical Industries. It was designed as a biosimilar of rituximab (MabThera/Rituxan), a chimeric monoclonal antibody that targets the CD20 antigen expressed on B cells, leading to B-cell depletion. TL011 was evaluated in clinical trials, including a Phase Ib study assessing its safety, pharmacokinetics, and pharmacodynamics compared to MabThera in patients with severe active rheumatoid arthritis who were also receiving methotrexate, as well as a Phase Ib study in patients with CD20-positive diffuse large B-cell lymphoma (DLBCL). However, Teva suspended and ultimately terminated the development of TL011 in 2012 due to regulatory and strategic considerations.
- Other names
- anti-CD20 monoclonal antibody TL011anti-CD-20 monoclonal antibody TL011anti-CD 20 monoclonal antibody TL011
02
Targets
Beyond the preview
Go deeper on TL011.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TL011.